ERs could be key to boosting HPV shots in High-Risk adults

NCT ID NCT06229353

Terminated Prevention Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explored whether giving the HPV vaccine in the emergency department (ER) could help protect adults aged 18-45 who haven't been fully vaccinated. Researchers enrolled 34 participants and offered the vaccine during their ER visit, with follow-up doses at 2 and 6 months. The goal was to see if the ER is a practical place to reach high-risk, under-immunized adults and improve vaccination rates against HPV, which can cause certain cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HPV vaccine (Gardasil 9)
What this could lead to: If successful, this approach could make it easier for high-risk adults to get the HPV vaccine during an ER visit, potentially preventing HPV-related cancers.
What could go wrong: The study was terminated early with only 34 participants, so results are limited. It may not show a clear benefit or be practical in other ER settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMA VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUMAN PAPILLOMA VIRUS

Contacts and locations

Locations

University of Alabama at Birmingham

Birmingham, Alabama, 35294-0022, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.